Fig. 3From: The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidenceProportion of infants (panel a and b) or of preterms (panel c and d) admitted for RSV infection in the three RSV epidemic seasons (2014–2015, 2015–2016 and 2016–2017). a and c Infants < 6 months of age; (b and d). Subgroup of infants < 3 months of ageBack to article page